Skye Bioscience Inc (NAS:SKYE)

$ 2.515 -0.035 (-1.37%) Market Cap: 77.36 Mil Enterprise Value: 10.14 Mil PE Ratio: 0 PB Ratio: 1.02 GF Score: 42/100

Skye Bioscience Inc at HC Wainwright Ophthalmology Virtual Conference Transcript
Aug 16, 2023
Skye Bioscience Inc at LD Micro Invitational Conference Transcript
Jun 07, 2023
Skye Bioscience Inc at Reed Smith Disruptive Growth Conference Transcript
Dec 05, 2022
Skye Bioscience Inc at Benzinga Global Small Cap Investor Conference (Virtual) Transcript
Dec 10, 2021
Skye Bioscience Inc at Benzinga Global Small Cap Conference (Virtual) Transcript
Oct 27, 2021

Skye Bioscience Inc at Benzinga Global Small Cap Conference (Virtual) Transcript

Oct 27, 2021 / 01:50PM GMT

Release Date Price: $14.71 (+3.25%)

Transcript 10-Q

Spencer Israel

Benzinga - Moderator

Punit Dhillon, he is the CEO and Chair of Skye Bioscience. I see him here. There he is.

Sir, good morning. How are we doing today?

Punit Dhillon

Skye Bioscience, Inc. - President, CEO & Chair

Hey, good morning. Such a nice day to be on the show again. Thanks.

Spencer Israel

Benzinga - Moderator

Yes, it's great to have you back. Guys, I see Punit's slides there. Let's get them up on the screen. We're good to go. The floor is yours, sir.

Punit Dhillon

Skye Bioscience, Inc. - President, CEO & Chair

Awesome. Well, pleasure being on the Bezinga show and thanks again for inviting us. This is incredible in terms of the Benzinga platform and we love getting the story out.

Skye Biosciences is a pharmaceutical cannabinoid company. Before I begin, I'm going to just remind everyone to please review the risk factors associated with some of the forward-looking statements I'm going to be making. Those can be found in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.